ASX Announcement

7 November 2024

Receipt of Research & Development Tax Incentive

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**), is pleased to advise that it has received multiple tranches of its research and development tax incentive (**RDTI**), totalling $3.23 million. This forms part of the Australian Government's R&D tax incentive program.

This total receipt is made up of approximately $1.24 million in relation to FY23, being a second tranche of funds following the submission of an amended FY23 tax lodgement, and $1.94 million representing the total R&D tax incentive for FY24. The balance represents interest accrued on the amounts.

The Company will use the funds received to fund ongoing operations focussed on preparing the second generation ColoSTAT® product for commercialisation and to repay the current loan balance of $1.15 million, which was announced to the ASX on 14 August 2024.

Rhythm will continue to participate in the government's R&D incentive program and will again submit an annual R&D claim lodgement following the conclusion of the 2025 financial year.

- ENDS -

Authorised for release by the Board.

For further information contact us via investor@rhythmbio.com:

Dr. David Atkins Chief Executive Officer	**Mr. Guy Carisbrooke** Financial Controller

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.